U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2018.

Cover of WHO treatment guidelines for isoniazid-resistant tuberculosis

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet].

Show details

Annex 3PICO question

In patients with isoniazid-resistant tuberculosis (other than MDR-TB), which treatment regimen composition and duration, when compared with six or more months of rifampicin-pyrazinamide-ethambutol, leads to a higher likelihood of success with least possible risk of harm?

PopulationIntervention1Comparator1Outcomes
Isoniazid-resistantTB cases:
with/out katG mutation and use of normal dose /high-dose isoniazid;
with/out inhA promoter mutation and use of normal dose /high-dose isoniazid;
in whom ethambutol, pyrazinamide or injectable agents are unlikely to work;previously treated for TB;with extensive disease;with HIV;
with HIV on antiretroviral therapy; children (0-14y); and with diabetes.
6REZ>6REZ
  • Treatment completed or bacteriological cure by end of treatment;
  • Treatment Failure +/- relapse;
  • Survival (or death);
  • Adverse reactions from anti-TB medicines (severity, type, organ class); and
  • Acquisition (amplification) of drug resistance.
6+RE + 2Z + fluoroquinolone6+REZ
6+REZ + fluoroquinolone6+REZ
6+REZ + injectable agent6+REZ

Footnotes

1

E=ethambutol; H=isoniazid; R=rifampicin; Z=pyrazinamide

© World Health Organization 2018.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third-party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “The translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK531417

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...